UN report: Lack of US funding will cause 4 milion additional AIDS deaths by 2029

The United Nations has warned that a permanent halt in US funding is expected to result in 4 million additional deaths from AIDS-related causes by 2029.
The General Assembly met on Thursday to study a UN progress report on the fight against HIV/AIDS.
The report says the US has been a leader in the global response to HIV for more than two decades, contributing more than 70 percent of donor funding.
But it notes that the administration of US President Donald Trump has paused the contributions since the end of January.
UN Deputy Secretary-General Amina Mohammed told the meeting that the cost of the reduction is stark.
She said closures of clinics and other disruptions to HIV services are putting adolescent girls and young women at especially greater risk, and that more babies are being born with HIV.
Mohammed said if US funding is permanently halted, the UN projects 4 million additional deaths and over 6 million new HIV infections by 2029.
She called on countries to reverse the funding declines, saying they must not allow themselves to "shatter the possibility of achieving the 2030 goal to end AIDS as a public health threat."
The UN report says nearly a quarter of the 39.9 million people living with HIV globally are not receiving life-saving treatment. It says one person is dying from HIV-related causes every minute.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Japan Today

3 days ago

• Japan Today

Israeli attacks kill 140 in Gaza in 24 hours, medics say

Mourners react during the funeral of Palestinians killed on Tuesday by Israeli fire while seeking aid in northern Gaza, according to Gaza's health ministry, at Al-Shifa Hospital, in Gaza City, June 18, 2025. REUTERS/Dawoud Abu Alkas By Nidal al-Mughrabi Israeli gunfire and strikes killed at least 140 people across Gaza in the past 24 hours, local health officials said, as some Palestinians in the Strip said their plight was being forgotten as attention has shifted to the air war between Israel and Iran. At least 40 of those killed over the past day died as a result of Israeli gunfire and airstrikes on Wednesday, Gaza's health ministry said. The deaths included the latest in near daily killings of Palestinians seeking aid in the three weeks since Israel partially lifted a total blockade on the territory. Medics said separate airstrikes on homes in the Maghazi refugee camp, the Zeitoun neighborhood and Gaza City killed at least 21 people, while five others were killed in an airstrike on an encampment in Khan Younis in southern Gaza. Fourteen more people were killed in Israeli fire at crowds of Palestinians awaiting aid trucks brought in by the United Nations along the Salahuddin road in central Gaza, medics said. Asked about the Salahuddin road incident, the Israel Defense Forces said that despite repeated warnings that the area was an active combat zone, individuals approached troops operating in the Nuseirat area in the central Gaza Strip in a manner that posed a threat to forces. Troops fired warning shots, it said, adding that it was unaware of injuries. Regarding other strikes, the IDF said it was "operating to dismantle Hamas military capabilities" while taking "feasible precautions to mitigate civilian harm". On Tuesday, Gaza's health ministry said 397 Palestinians among those trying to get food aid had been killed and more than 3,000 wounded since aid deliveries restarted in late May. Some in Gaza expressed concern that the latest escalations in the war between Israel and Hamas that began in October 2023 would be overlooked due to the new Israel-Iran conflict. "People are being slaughtered in Gaza, day and night, but attention has shifted to the Iran-Israel war. There is little news about Gaza these days," said Adel, a resident of Gaza City. "Whoever doesn't die from Israeli bombs dies from hunger. People risk their lives every day to get food, and they also get killed and their blood smears the sacks of flour they thought they had won," he told Reuters via a chat app. 'FORGOTTEN' Israel is now channelling much of the aid into Gaza through a new U.S.- and Israeli-backed group, the Gaza Humanitarian Foundation, which uses private U.S. security and logistics firms and operates a handful of distribution sites in areas guarded by Israeli forces. Israel has said it will continue to allow aid into Gaza, home to more than 2 million people, while ensuring it doesn't get to Hamas. Hamas denies seizing aid, saying Israel uses hunger as a weapon. Philippe Lazzarini, head of the U.N. agency for Palestinian refugees, called the current system for distributing aid "a disgrace & a stain on our collective consciousness", in a post on X on Wednesday. The war in Gaza was triggered when Hamas-led militants attacked Israel in October 2023, killing 1,200 and taking about 250 hostages, according to Israeli allies. Israel's subsequent military assault has killed nearly 55,600 Palestinians, according to Gaza's health ministry, displaced almost all the territory's residents, and caused a severe hunger crisis. The World Food Program called on Wednesday for a big increase in food distribution in Gaza, saying that the 9,000 metric tons it had dispatched over the last four weeks inside Gaza represented a "tiny fraction" of what was needed. "The fear of starvation and desperate need for food is causing large crowds to gather along well-known transport routes, hoping to intercept and access humanitarian supplies while in transit," the WFP said in a statement. "Any violence resulting in starving people being killed or injured while seeking life-saving assistance is completely unacceptable," it added. Palestinians in Gaza have been closely following Israel's air war with Iran, long a major supporter of Hamas. "We are maybe happy to see Israel suffer from Iranian rockets, but at the end of the day, one more day in this war costs the lives of tens of innocent people," said 47-year-old Shaban Abed, a father of five from northern Gaza. "We just hope that a comprehensive solution could be reached to end the war in Gaza, too. We are being forgotten." © Thomson Reuters 2025.

Japan Times

5 days ago

• Japan Times

U.S. pharma bets big on China to snap up potential blockbuster drugs

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive said. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone," payments, while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are ... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one health care analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global health care group. In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio. That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals. By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung said. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based health care investment firm TCGX.

NHK

6 days ago

• NHK

US startup to launch AI healthcare assistant in Japan

A US startup has announced plans to roll out an AI assistant in Japan to help ease the country's shortage of medical workers. Hippocratic AI CEO Munjal Shah said he hopes the AI will eventually be able to detect health risks faced by elderly patients and alert human staff. He added the program will be especially useful in Japan, which has one of the highest proportions of people over 65 in the world. "It's a place where you're going to need a lot more healthcare workers and the only real answer to this is going to be AI," said Shah. The AI assistant currently provides patients with non-diagnostic support. It can make appointments, monitor their condition after hospitalization, and manage medication. The company says the program is already being used by 2.5 million people around the world. Hippocratic AI entered a partnership with a Tokyo-based venture firm in May, with plans to make the AI assistant available in Japan later this year.